Payer Cost Strategies Weigh On CV Fixed-Dose Combinations
Executive Summary
Fixed-dose combination drugs represent an attractive marketing prospect for drug makers given their relative low development cost and the opportunity they represent to extend a brand's lifecycle
You may also be interested in...
FDA Approval Obtained, Other Hurdles Remain For Daiichi's Tribenzor
Daiichi Sankyo obtained U.S. FDA approval for its triple combination fixed-dose hypertension drug Tribenzor on July 23, but the bigger challenges of building a market and winning payer adoption of a product in which two of three components are available as generics remains
FDA Approval Obtained, Other Hurdles Remain For Daiichi's Tribenzor
A triple combination, fixed-dose therapeutic for hypertension, Tribenzor faces a market in which many payers are leery of products with components also available as generics.
FDA Approval Obtained, Other Hurdles Remain For Daiichi's Tribenzor
A triple combination, fixed-dose therapeutic for hypertension, Tribenzor faces a market in which many payers are leery of products with components also available as generics.